



Trading in ChromoGenics starts at Nasdaq First North on March 23 after approved listing application

ChromoGenics AB (publ), a leading provider of dynamic glass with controllable heat- and light transmission for solar control and energy efficiency, implements listing of shares and warrants on Nasdaq First North after approved listing application. The first trading day for the shares and the warrants will be March 23rd 2017.

Ahead of the listing, ChromoGenics completed an oversubscribed issue of new shares bringing in 117.3 MSEK, before deduction of issue expenses and settlements of shareholder loans and guarantee fees. In addition, up to 1 MSEK may be subject to normal market stabilization and / or involve the use of over-allotment option. ChromoGenics receive in connection with the rights issue just over 2100 new shareholders.

G&W Fondkommission is the financial advisor to ChromoGenics in connection with the transaction and appointed as Certified Adviser for the planned listing on Nasdaq First North Stockholm.

This information is such that ChromoGenics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 CET on March 20, 2017.

Every care has been taken in the translation of this interim report. In the event of discrepancies, the Swedish original will supersede the English translation.

Contact:

Thomas Almesjö, CEO
Susanne Andersson, CFO & Head of Communications
Tel: +46 18 430 0430
E-mail: info@chromogenics.com

About ChromoGenics

ChromoGenics is a leader in dynamic glass with controllable heat- and light transmission. The company's unique electrochromic technology ConverLight™, provides sustainable solar control with increased indoor comfort and energy efficiency. In 2016 the company started commercial sales to real estate projects in Scandinavia.

ChromoGenics is located in Uppsala and has about 20 employees. The technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share will be listed on Nasdaq First North Stockholm from March 23rd 2017. G&W Fondkommission is appointed Certified Adviser. www.chromogenics.com